StemCell Institute (7096) · FactRestated
Transition to consolidated financial reporting as subsidiary businesses enter full-scale operations
First written in FY2026-H1. 1 of 2 entries say "Restated". Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Ongoing review of the consolidation and equity-method scopes based on materiality criteriaA theme 74 companies write about · 0 as a headwind · 4 as a tailwind
21 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 74 companies compared. The sentences above are computed from all 74.Full recordFilings, disclosures and news, newest first
- FY2026RestatedAnnual report
「As the subsidiaries' businesses reached full scale and their contribution to performance increased, the Company transitioned to consolidated reporting from the second quarter, or interim period, of the current consolidated fiscal year.」
The full-year report confirms the policy and fact of transitioning to consolidated reporting from the interim period following the increased importance of STEMCELL INNOVATIONS and ミルケア. - FY2026-H1First statedAnnual report
「The impact of the subsidiaries' businesses on performance had previously been immaterial, but as their businesses reached full scale and their contribution to performance increased, the Company transitioned to consolidated reporting from the current interim consolidated accounting period and included 2 companies in the scope of consolidation.」
As the importance of the Singapore subsidiary and ミルケア increased, the Company transitioned to consolidated reporting and included the 2 companies as consolidated subsidiaries for the interim consolidated accounting period from April to September 2025.